Zhi-Ping Ruan
Overview
Explore the profile of Zhi-Ping Ruan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
356
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zheng H, Jiang A, Gao H, Liu N, Zheng X, Fu X, et al.
Front Oncol
. 2022 Oct;
12:894835.
PMID: 36203439
Background: Patients with extensive-stage small-cell lung cancer (ES-SCLC) have high recurrence rates and bleak prognosis. This multicenter real-world study aimed to explore the efficacy and safety of anlotinib combined with...
2.
Zheng H, Jiang A, Gao H, Liu N, Zheng X, Fu X, et al.
Cancer Manag Res
. 2022 Aug;
14:2273-2287.
PMID: 35942069
Purpose: Anlotinib, an antiangiogenic multi-target tyrosine kinase inhibitor (TKI), has shown favorable anticancer efficacy and acceptable safety in treating extensive-stage small cell lung cancer (ES-SCLC) in some clinical studies. This...
3.
Jiang A, Zheng H, Liu N, Zhao R, Ma Y, Bai S, et al.
Cancer Control
. 2021 Oct;
28:10732748211050581.
PMID: 34654345
Objectives: Numerous studies have elucidated that circulating tumor cells (CTCs) have significant prognostic value in various solid tumors. However, the prognostic value of CTCs in small cell lung cancer (SCLC)...
4.
Jiang A, Ren M, Liu N, Gao H, Wang J, Zheng X, et al.
Int J Med Sci
. 2021 Jan;
18(1):226-238.
PMID: 33390791
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide, and the prognosis of HNSCC remains bleak. Numerous studies revealed that the tumor mutation burden (TMB)...
5.
Liu Z, Zhu L, Liu J, Pu Z, Ruan Z, Chen J
Aging (Albany NY)
. 2020 Nov;
12(24):25172-25188.
PMID: 33223512
Anti-vascular endothelial growth factor (anti-VEGF) drugs have long been the only first-line treatment for advanced or unresectable hepatocellular carcinoma (HCC). Recently, the combination of bevacizumab (an anti-VEGF drug) and atezolizumab...
6.
Le D, Zhang Y, Xu Y, Guo L, Ruan Z, Burgess K, et al.
PLoS One
. 2020 Aug;
15(7):e0235569.
PMID: 32735584
The palm family (Arecaceae) is of high ecological and economic value, yet identification in the family remains a challenge for both taxonomists and horticulturalists. The family consists of approximately 2600...
7.
Jiang A, Liu N, Ali Said R, Ren M, Gao H, Zheng X, et al.
Cancer Manag Res
. 2020 Jul;
12:4969-4979.
PMID: 32612384
Background: Cancers of the gastrointestinal (GI) tract and its associated excretory glands are one of the most common causes of cancer-related death worldwide, and these patients are more likely to...
8.
Jiang A, Shi X, Liu N, Gao H, Ren M, Zheng X, et al.
BMC Infect Dis
. 2020 Jul;
20(1):452.
PMID: 32600270
Background: Bacterial infections are the most frequent complications in patients with malignancy, and the epidemiology of nosocomial infections among cancer patients has changed over time. This study aimed to evaluate...
9.
Bai Y, Du L, Jing L, Tian T, Liang X, Jiao M, et al.
Cancer Manag Res
. 2019 Jun;
11:4283-4295.
PMID: 31190994
The prognostic and clinicopathological role of pretreatment thrombocytosis in cancer has been widely studied, but conclusions in endometrial cancer (EnCa) remain controversial. Therefore, we conducted a meta-analysis to assess the...
10.
Wu T, Ma X, Wang G, Li Q, Li M, Guo J, et al.
Sci Rep
. 2017 Jul;
7(1):4412.
PMID: 28667286
ABO blood types are associated with the prognosis of several malignancies. However, the role of the ABO blood type in hepatocellular carcinoma (HCC) remains elusive. Here, we evaluated the prognostic...